Rivia raises €13M to bring agentic AI to clinical trials


The Zurich-based startup, which previously raised €3M to unify fragmented trial data, has secured a larger round to build AI agents that actively manage the complex operational layer of running a clinical trial.


Clinical trials are, by almost any measure, one of the most information-intensive processes in modern medicine, and one of the least efficiently managed. A single Phase III trial can generate data across dozens of sites, hundreds of variables, and multiple regulatory frameworks simultaneously.

The software tools that research teams use to manage this complexity were largely designed in an earlier era, when the primary goal was storage rather than intelligence.

Rivia, a Zurich-based company that has been building a unified data platform for biotech clinical trials since 2022, announced today that it has raised €13 million in a new funding round to expand what it describes as an agentic data engine, a system in which AI agents actively surface insights, flag anomalies, and help coordinate the operational layer of a trial, rather than simply storing and visualising data.

The company raised €3 million in seed funding in June 2024, led by Speedinvest, to build the foundational data infrastructure. The new round represents a significant step up in ambition and capital, reflecting both the progress Rivia says it has made with early biotech clients and the broader shift in enterprise AI towards systems that act, not just analyse.

The 💜 of EU tech

The latest rumblings from the EU tech scene, a story from our wise ol’ founder Boris, and some questionable AI art. It’s free, every week, in your inbox. Sign up now!

The problem with trial data

The core challenge Rivia is addressing is fragmentation. Clinical trial data flows from electronic data capture systems, patient wearables, laboratory instruments, site management software, and regulatory filings, often through different vendors, in different formats, with different update cycles.

Research teams spend a substantial portion of their time simply reconciling these data sources rather than drawing insight from them.

Rivia’s platform, as described in its earlier materials, integrates these data streams into a single environment. Its AI layer, which the company is now calling an agentic data engine, goes a step further, using large language model-based agents to proactively answer questions about trial status, identify enrolment risks before they become delays, and flag data quality issues in near-real-time.

The company says it has deployed the platform with biotech clients running active trials, though it has not disclosed the number of clients or the scale of trials covered.

Agentic AI meets regulated environments

Clinical trials sit in one of the most tightly regulated environments in any industry. The US Food and Drug Administration and the European Medicines Agency impose strict requirements on data integrity, audit trails, and validation documentation.

Any AI system operating in this environment must not only perform well but be explainable and auditable in ways that general-purpose AI tools are not designed to be.

This regulatory complexity is both Rivia’s challenge and its moat. A company that can build AI agents that operate inside the FDA and EMA compliance frameworks, rather than around them, has a defensible position that a general-purpose AI tool cannot easily replicate.

Whether Rivia has already achieved that level of regulatory readiness, or is building towards it, was not clear from public communications.

The broader market for AI in clinical trials has attracted significant capital in 2025 and 2026, with competitors including Medable, Veeva, and a cohort of smaller startups competing on different parts of the trial stack.

Rivia’s bet is that the data layer, the substrate that connects everything else, is the highest-value position in the architecture. With €13 million now in the bank, it has the runway to test that thesis.



Source link

Leave a Reply

Subscribe to Our Newsletter

Get our latest articles delivered straight to your inbox. No spam, we promise.

Recent Reviews


Do you ever walk past a person on the streets exhibiting mental health issues and wonder what happened to their family? I have a brother—or at least, I used to. I worry about where he is and hope he is safe. He hasn’t taken my call since 2014.

James and his brother as young children playing together before his brother became sick. James is on the right and his brother is on the left.

James and his brother as young children playing together before his brother became sick. James is on the right and his brother is on the left.

When I was 13, I had a very bad day. I was in the back of the car, and what I remember most was the world-crushing sound violently panging off every surface: he was pounding his fists into the steering wheel, and I worried it would break apart. He was screaming at me and my mother, and I remember the web of saliva and tears hanging over his mouth. His eyes were red, and I knew this day would change everything between us. My brother was sick.

Nearly 20 years later, I still have trouble thinking about him. By the time we realized he was mentally ill, he was no longer a minor. The police brought him to a facility for the standard 72-hour hold, where he was diagnosed with paranoid delusional schizophrenia. Concluding he was not a danger to himself or others, they released him.

There was only one problem: at 18, my brother told the facility he was not related to us and that we were imposters. When they let him out, he refused to come home.

My parents sought help and even arranged for medication, but he didn’t take it. Before long, he disappeared.

My brother’s decline and disappearance had nothing to do with the common narratives about drug use or criminal behavior. He was sick. By the time my family discovered his condition, he was already 18 and legally independent from our custody.

The last time he let me visit, I asked about his bed. I remember seeing his dirty mattress on the floor beside broken glass and garbage. I also asked about the laptop my parents had gifted him just a year earlier. He needed the money, he said—and he had maxed out my parents’ credit card.

In secret from my parents, I gave him all the cash I had saved. I just wanted him to be alright.

My parents and I tried texting and calling him; there was no response except the occasional text every few weeks. But weeks turned into months.

Before long, I was graduating from high school. I begged him to come. When I looked in the bleachers, he was nowhere to be seen. I couldn’t help but wonder what I had done wrong.

The last time I heard from him was over the phone in 2014. I tried to tell him about our parents and how much we all missed him. I asked him to be my brother again, but he cut me off, saying he was never my brother. After a pause, he admitted we could be friends. Making the toughest call of my life, I told him he was my brother—and if he ever remembers that, I’ll be there, ready for him to come back.

I’m now 32 years old. I often wonder how different our lives would have been if he had been diagnosed as a minor and received appropriate care. The laws in place do not help families in my situation.

My brother has no social media, and we suspect he traded his phone several years ago. My family has hired private investigators over the years, who have also worked with local police to try to track him down.

One private investigator’s report indicated an artist befriended my brother many years ago. When my mother tried contacting the artist, they said whatever happened between them was best left in the past and declined to respond. My mom had wanted to wish my brother a happy 30th birthday.

My brother grew up in a safe, middle-class home with two parents. He had no history of drug use or criminal record. He loved collecting vintage basketball cards, eating mint chocolate chip ice cream, and listening to Motown music. To my parents, there was no smoking gun indicating he needed help before it was too late.

The next time you think about a person screaming outside on the street, picture their families. We need policies and services that allow families to locate and support their loved ones living with mental illness, and stronger protections to ensure that individuals leaving facilities can transition into stable care. Current laws, including age-based consent rules, the limits of 72-hour holds, and the lack of step-down or supported housing options, leave too many families without resources when a serious diagnosis occurs.

Governments and lawmakers need to do better for people like my brother. As someone who thinks about him every day, I can tell you the burden is too heavy to carry alone.

James Finney-Conlon is a concerned brother and mental health advocate. He can be reached at [email protected].



Source link